**Title:** "Medpace Holdings Reports Robust 9.28% Revenue Growth: Capitalizing on Market Demand and R&D Innovations"

Performance Review

Medpace Holdings' total operating revenue as of March 31, 2025 was RMB558.57 million, up 9.28% from RMB511.04 million as of March 31, 2024. This growth indicates improvement in the company's operating revenue, possibly benefiting from business expansion and increased market demand.

Key Financial Data

1. Medpace's revenue growth is mainly driven by the increase in new clients and projects.

2. The company expects its strong performance in the digestive drug field to account for over 60% of the overall growth.

3. Medpace plans to increase R&D investment to promote product innovation and commercialization.

4. The company expands its market share by improving service quality and efficiency, leading to revenue growth.

Peer Comparison

1. Industry-wide analysis: The clinical research industry has been growing steadily in recent years, especially in the biopharmaceutical and medical device sectors, and is expected to continue its growth trend, providing a good external environment for Medpace's revenue growth.

2. Peer evaluation analysis: Medpace's revenue growth rate of 9.28% is at a medium-to-high level in the industry, showing its competitive advantage in the market.

Summary

Medpace Holdings' revenue growth in 2025 is affected by various factors, including the increase in new clients and projects, the rise in market demand, and the increase in R&D investment. Its performance in the industry is better than the average, showing strong market competitiveness.

Opportunities

1. The growing market demand provides Medpace with good development opportunities, especially in the biopharmaceutical field.

2. By acquiring new clients and increasing projects, Medpace can further enhance its revenue.

3. The increase in R&D investment will drive product innovation and enhance the company's market competitiveness.

4. Improving service quality and efficiency will help expand the market share and bring more revenue sources.

Risks

1. Intensified market competition may affect Medpace's market share and profitability.

2. External policy pressure may affect the overall industry development, and policy changes need to be closely monitored.

3. Failure to effectively maintain service quality and efficiency may lead to customer loss and revenue decline.

4. Fluctuations in market demand may lead to uncertainty in revenue growth, and market research and analysis need to be strengthened.